Printer Friendly


 -- Articles In 'Wounds' Show CT102 Enhances Wound
 Healing And Saves Healthcare Costs --
 EAST SETAUKET, N.Y., Aug. 10 /PRNewswire/ -- Curative Technologies, Inc. (CTI) (NASDAQ: CURE) today announced that the results of two controlled studies have been published providing encouraging evidence that the company's novel investigational wound healing treatment, CT102, is efficacious and more cost-effective in healing chronic non-healing wounds than conventional treatments. The studies appear in today's issue of the journal 'Wounds.'
 "In this cost conscious healthcare environment, one must do more than just prove a product is efficacious -- one must also show that it is a cost-effective treatment. There is a tremendous need for wound healing therapies that meet both criteria," said Russell B. Whitman, chairman, president and CEO. "The simultaneous publication of these studies in 'Wounds' is an important step in the process of establishing the utility of this exciting technology."
 CTI is developing CT102, a topical treatment containing a naturally occurring complex mixture of several growth factors derived from pooled human blood platelets, to treat chronic non-healing wounds. Such wounds are a common diabetic ailment which affects more than two million Americans. The wounds, many of which remain open sores for months or years, often lead to gangrene and can result in amputation. In the United States, diabetic foot problems account for about 60,000 lower limb amputations each year at a total cost of about $1 billion annually.
 A Phase II clinical study of CT102, conducted by a team of independent medical specialists, found that the most effective dosage of the therapy haled 80 percent of wounds versus 29 percent of those treated with a placebo. The randomized, double-blind, dose-ranging study followed 70 patients over 20 weeks. Each patient was treated for 140 days or until the wound was completely healed. Efficacy was determined by evaluating complete healing and reduction in area and volume of wounds in all patients meeting protocol requirements.
 "The observed healing rates were very encouraging and constitute a significant step forward in the development of an effective treatment for chronic non-healing wounds," said G. Allen Holloway, M.D., of the Maricopa Medical Center in Phoenix, Ariz., the study's lead author. "No significant side effects were associated with CT102 compared to the placebo."
 The cost efficacy study published in 'Wounds' evaluated the economic impact of treating patients with CT102 and a conventional treatment including a placebo. Judith D. Bentkover, Ph.D., and Annette H. Champion of the health economics group of Arthur D. Little Inc., found that the medical cost of healing a diabetic foot ulcer patient with CT102 was 38 percent, or an average of approximately $13,600, less than the placebo treatment.
 Efficacy data from the clinical trial and 1992 medical costs, as determined by research conducted by Arthur D. Little, were used to construct an economic model of the diagnosis and treatment of diabetic patients with non-healing foot ulcers. Costs were limited to direct costs; economic impact was considered from the perspective of all payers of medical care, including patients, insurers and government.
 "We found that the wound healing approach incorporating CT102 as part of a comprehensive wound management program is cost-effective over several treatment options," said Dr. Bentkover. "And, when one considers the health and economic consequences of wounds that do not heal for months or even years, it is likely that CT102 can significantly improve patients' quality of life and present the healthcare system with impressive savings."
 CT102 is currently in pivotal clinical trials in the United States and Europe for diabetic foot ulcers. If approved by the Food and Drug Administration, CT102 will be available as a prescription product through traditional pharmaceutical marketing and distribution channels, and will also be marketed through CTI's Wound Care Center(R) network, a group of hospital-based centers focusing on wound management.
 At present, CTI manages or has contracts to manage more than 50 Wound Care Centers throughout the United States which provide patients with a comprehensive multifaceted approach to wound healing including, in some cases, the use of Procuren(R) therapy, a complex mixture of autologous growth factors isolated from a patient's blood. More than 32,000 patients have been treated at these Wound Care Centers with more than 12,000 receiving growth factor therapy.
 -0- 8/10/93
 /NOTE TO EDITORS: Curative Technologies has a nationwide network of Wound Care Centers providing novel wound care. Please call Kathryn Comba at, 212-696-4455, for the name of the facility nearest you./
 /CONTACT: Russell B. Whitman of Curative Technologies, Inc., 516-689-7000, or Anthony J. Russo, Ph.D., of Noonan-Russo Communications, Inc., 212-696-4455, for Curative Technologies, Inc./

CO: Curative Technologies, Inc. ST: New York IN: MTC SU: PDT

LD -- NY008 -- 1077 08/10/93 09:35 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 10, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters